Latest News

Big multiple sclerosis breakthrough: Phase 1 trial safely resets patients' immune systems and reduces attack on myelin protein

A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and dramatically reduced patients' immune systems' reactivity to myelin by 50 to 75 percent. The therapy used billions of patients' own specially processed blood cells to create tolerance to myelin, the insulating layer that forms around nerves. In MS, the immune system attacks myelin. The approach left the normal immune system intact.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • E-cigarettes significantly reduce tobacco cravings, study suggests

  • Coping strategies therapy significantly improves dementia carers' mental health, quality of life

  • Fathers' engagement with baby depends on mother

  • Unstable child care can affect children by age four

  • Self-regulation intervention boosts school readiness of at-risk children, study shows

  • Rejecting unsuitable suitors is easier said than done

  • Reported opioid abuse in pregnant women more than doubles in 14 years

  • Computerized cognitive training has modest benefits for cognitively healthy older adults

  • Gamification for behavior change: What is it and how is it useful?

  • Spatial memory: Orientation study suggests that a visual image of the intermediate spatial environment exists in brain

  •